All In Biotech

NDA 050778 · Pfizer INC

Ellence

Epirubicin Hydrochloride · Injection

NovelPriority reviewOrphan

Last checked: Nov 19, 2026Latest source record: Nov 25, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1999

Sep 15, 1999

Approved uses

2

Original approval plus efficacy supplements

Registered trials

608

204 Phase 3, 77 recruiting

FAERS reports

6,498

6,286 serious, 478 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: CARDIAC TOXICITY, SECONDARY MALIGNANCIES, EXTRAVASATION AND TISSUE NECROSIS, and SEVERE MYELOSUPPRESSION • Cardiac Toxicity: Myocardial damage, including acute left ventricular failure, can occur with ELLENCE. The risk of cardiomyopathy is proportional to the cumulative exposure with incidence rates from 0.9% at a cumulative dose of 550 mg/m 2 , 1.6% at 700 mg/m 2 , and 3.3% at 900 mg/m 2 . The risk of cardiomyopathy is further increased with concomitant cardiotoxic therapy. Assess left ventricular ejection fraction (LVEF) before and regularly during and after treatment with ELLENCE [see Warnings and Precautions (5.1) ] . • Secondary Malignancies: Secondary acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) occur at a higher incidence in patients treated with anthracyclines, including ELLENCE [see Warnings and Precautions (5.2) ] . • Extravasation and Tissue...

What it is approved for

From the label in effect Jul 24, 2026.

ELLENCE is indicated as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer [see Clinical Studies (14.1) ] . ELLENCE is an anthracycline topoisomerase inhibitor indicated as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer ( 1 ).

Mechanism: Epirubicin is an anthracycline cytotoxic agent. Although it is known that anthracyclines can interfere with a number of biochemical and biological functions within eukaryotic cells, the precise mechanisms of epirubicin's cytotoxic and/or antiproliferative properties have not been completely elucidated. Epirubicin forms a complex with DNA by intercalation of its planar rings between nucleotide base pairs, with consequent inhibition of nucleic acid (DNA and RNA) and protein synthesis. Such intercalation triggers DNA cleavage by topoisomerase II, resulting in cytocidal activity. Epirubicin also...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Mar 2, 2005 Supplement 8 · Efficacy LabelLetter
  • Sep 15, 1999 Original approval · Type 1 - New Molecular Entity · priority review LabelReviewLetter
2 products under this application
  • ELLENCE · EPIRUBICIN HYDROCHLORIDE 200MG/100ML (2MG/ML) · INJECTABLE, INJECTION · Prescription · TE AP
  • ELLENCE · EPIRUBICIN HYDROCHLORIDE 50MG/25ML (2MG/ML) · INJECTABLE, INJECTION · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Epirubicin" as an intervention, any sponsor and status, largest first.

All 608 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • myelosuppression726
  • nausea553
  • white blood cell count decreased493
  • alopecia459
  • vomiting419
  • febrile neutropenia371
  • pyrexia339
  • asthenia326
  • neutropenia278
  • hepatic function abnormal274
  • neutrophil count decreased272
  • off label use235

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200433
200514
200620
200762
200867
200950
2010137
2011269
2012334
2013135
2014120
2015185
2016169
2017153
2018361
2019337
2020290
2021388
2022709
2023722
2024838
2025636
2026469

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part B: Ellence* (Epirubicin HCL*) · HCPCS J9178

2024 spending

$4K

Beneficiaries

27

75 claims

Per beneficiary

$146

2024 ASP limit $1.46 per unit

View as table
YearSpending
2020$11,129
2021$8,402
2022$8,612
2023$5,569
2024$3,936

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 2,003 on PubMed

Sponsor: Pfizer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.